If the emergence of Covid-19 pandemic has taught the world one thing, it would be to invest more in medical infrastructure. The research and development of lifesaving drugs and preventive vaccines has hit a new high, and pioneering this unprecedented growth is Sanjeev Nanda’s PharmAid.
For the uninitiated, PharmAid was started by British-India businessman Sanjeev Nanda, who also serves as its Managing Director. Established in 2017, the company is a joint venture between Rostec State Corporation, and Nanda’s Ishvan Pharmaceuticals Ltd, a leading pharma company based in Dubai.
According to Sanjeev Nanda, the establishment of PharmAid was aimed at contributing to the Russian Federation’s strategy to achieve independence from the import of essential drugs. “Our aim is to assist Russia in the creation of an environment that enables the advancement of modern medicine in the country,” says Nanda.
Fanning out in a phased manner, PharmAid works towards producing essential drugs and vaccines in Russia that are high on quality and low on price at the same time. The joint venture’s goal is to help the country ensure sustainable development while maintaining significant savings for the healthcare budget.
Ever since its inception, PharmAid has been making positive strides towards transforming the healthcare scenario in Russia. The emerging pharma leader is working ardently towards creating a state-of-the-art pharmaceutical infrastructure through the establishment of a holistic pharma ecosystem.
“With PharmAid, we are working on three key objectives – transfer of technologies, localized production of innovative combined immunobiological drugs in Russia, and ensuring increased availability of effective therapy for Russian patients. With our cutting-edge mRNA technologies, we are leading the way in this field,” says PharmAid MD Sanjeev Nanda.
The venture’s active projects include the research and development of a vast portfolio of vaccines and immunobiological preparations. These include varicella vaccine, rotavirus vaccine, human papillomavirus vaccine, meningococcal vaccine, monoclonal antibody for rabies, and MMR (measles, Mumps, Rubella) vaccine.
